
Quarterly report 2025-Q2
added 08-13-2025
DURECT Corporation Net Debt 2011-2026 | DRRX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt DURECT Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.4 M | -41.4 M | -27.5 M | 269 K | 15.1 M | -8.44 M | -9.46 M | 14.4 M | 41.6 M | 47.2 M | -7.84 M | -11.2 M | -8.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 47.2 M | -41.4 M | -505 K |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M | ||
|
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M | ||
|
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | $ 21.64 | - | $ 2.06 B | ||
|
Canopy Growth Corporation
CGC
|
193 M | $ 1.05 | -2.34 % | $ 113 M | ||
|
Cronos Group
CRON
|
-1.07 B | $ 2.59 | -0.77 % | $ 1.34 B | ||
|
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | ||
|
Cumberland Pharmaceuticals
CPIX
|
-12.7 M | $ 3.82 | -1.29 % | $ 53.7 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-931 M | - | -0.1 % | $ 2.03 B | ||
|
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M | ||
|
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | ||
|
Evoke Pharma
EVOK
|
-2.96 M | - | - | $ 36.6 M | ||
|
Emergent BioSolutions
EBS
|
338 M | $ 10.75 | -2.54 % | $ 550 M | ||
|
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | ||
|
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | ||
|
Evolus
EOLS
|
36.3 M | $ 4.28 | -0.46 % | $ 265 M | ||
|
China Pharma Holdings
CPHI
|
-4.73 M | $ 0.69 | 7.78 % | $ 12 M | ||
|
Harrow Health
HROW
|
173 M | $ 47.33 | -2.73 % | $ 1.54 B | ||
|
OrganiGram Holdings
OGI
|
90.7 M | $ 1.29 | -1.91 % | $ 402 M | ||
|
Pacira BioSciences
PCRX
|
317 M | $ 21.5 | -1.08 % | $ 994 M | ||
|
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | ||
|
Bausch Health Companies
BHC
|
21.1 B | $ 5.86 | -3.62 % | $ 2.14 B | ||
|
Tilray
TLRY
|
14.4 M | $ 7.49 | -1.77 % | $ 4.63 B | ||
|
Sundial Growers
SNDL
|
-28.4 M | $ 1.51 | 0.33 % | $ 3.37 M | ||
|
Neoleukin Therapeutics
NLTX
|
-146 M | - | - | $ 193 M | ||
|
cbdMD
YCBD
|
-521 K | $ 0.69 | -8.98 % | $ 2.98 M | ||
|
Perrigo Company plc
PRGO
|
3.05 B | $ 14.37 | -1.61 % | $ 1.97 B | ||
|
Organogenesis Holdings
ORGO
|
-131 M | $ 3.72 | -1.2 % | $ 490 M | ||
|
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | ||
|
Aurora Cannabis
ACB
|
285 M | $ 3.38 | -1.89 % | $ 86.3 M | ||
|
ProPhase Labs
PRPH
|
-6.41 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | ||
|
Rockwell Medical
RMTI
|
691 K | $ 1.01 | -7.34 % | $ 23.6 M | ||
|
Relmada Therapeutics
RLMD
|
-2.5 M | $ 3.9 | -2.63 % | $ 117 M | ||
|
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
-34 M | $ 12.07 | 0.96 % | $ 857 M | ||
|
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-5.29 M | $ 2.78 | -2.46 % | $ 3.45 M | ||
|
Solid Biosciences
SLDB
|
-70.9 M | $ 6.15 | -3.98 % | $ 251 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-50.3 M | - | - | $ 55.5 M | ||
|
SCYNEXIS
SCYX
|
-31.1 M | $ 0.78 | -2.71 % | $ 37.3 M | ||
|
Veru
VERU
|
-20.9 M | $ 2.26 | -1.74 % | $ 305 M | ||
|
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | ||
|
TherapeuticsMD
TXMD
|
3.68 M | $ 2.41 | -0.82 % | $ 25.2 M | ||
|
Viatris
VTRS
|
16.8 B | $ 15.89 | -1.48 % | $ 19.3 B |